Publisher Future Science Group has announced the relaunch of Oncology Central, the information hub designed exclusively for medical professionals in the field of oncology. Oncology is a fast-moving, multidisciplinary field at the forefront of medical research and Oncology Central unites all aspects to support multilateral progression in the field.
Oncology Central is a free-of-charge platform where peer-reviewed journal articles from highly valued journals, regular cancer news updates, exciting multimedia content, and exclusive features can all be digested quickly and easily. With even more content, the fully redesigned Oncology Central is even easier to navigate, saving time when you need to search by a specific disease area or topic.
The relaunch sees the addition of new site features including a dedicated Pipelines and Trials section, which allows easy access to all phase trials and pipelines by discipline breakdown so you can keep an eye on future therapeutic prospects. Webinars have also been introduced to keep users up to speed on vital areas and allow opportunity to pose questions to fellow experts.
In celebration of the relaunch of Oncology Central, a special collection of recent peer-reviewed articles discussing cancer immunotherapy strategies are being featured. These include an excellent review of anti-PD1 and anti-PD-L1 therapies in the treatment of metastatic melanoma – a key topic highlighted in the Plenary Session of the recent ASCO meeting.
Interested parties may visit http://www.oncology-central.com/immunotherapy-supp/ register for access.
